• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为小分子PD-L1抑制剂的含氨基酸喹唑啉衍生物的设计、合成、评估及分子模拟

Design, synthesis, evaluation and molecular modeling of quinazoline derivatives bearing amino acids as small-molecule PD-L1 inhibitors.

作者信息

Liu Han, Chen Roufen, Yuan Dandan, Xing Yidan, Ding Xueyan, Wu Xingye, Gao Yali, Ma Junjie

机构信息

School of Medicine, Huaqiao University, Quanzhou, 362000, China.

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.

出版信息

J Comput Aided Mol Des. 2025 Jul 18;39(1):55. doi: 10.1007/s10822-025-00635-y.

DOI:10.1007/s10822-025-00635-y
PMID:40679557
Abstract

Herein, we reported a series of quinazoline derivatives bearing amino acids by introducing a rigid pyrimidine structure between the 2 and 3-positions of the biphenyl and establishing an ionic interaction with Lys124 of PD-L1. Evaluation of the PD-1/PD-L1 inhibitory activity identified compound 7, which exhibited the most potent inhibitory activity with an IC value of 7.21 nM. Molecular docking was performed to demonstrate that the carboxyl group of amino acid in the tail established an ionic interaction with the ε-NH of Lys124, enhancing the binding. Importantly, molecular dynamics study revealed that the nitrogen atom in the nicotinonitrile formed water-mediated interactions with Asn63 of PD-L1, that stabilized the binding of the compound to PD-L1, providing an important and reasonable explanation for the introduction of nicotinonitrile to enhance inhibitory activity. Our study provides valuable guidance for further design of potent quinazoline-based small-molecule PD-L1 inhibitors, and identifies the compound 7 that is a promising lead compound and deserves further investigation.

摘要

在此,我们报道了一系列通过在联苯的2位和3位之间引入刚性嘧啶结构并与PD-L1的Lys124建立离子相互作用而带有氨基酸的喹唑啉衍生物。对PD-1/PD-L1抑制活性的评估确定了化合物7,其表现出最有效的抑制活性,IC值为7.21 nM。进行分子对接以证明尾部氨基酸的羧基与Lys124的ε-NH建立了离子相互作用,增强了结合。重要的是,分子动力学研究表明烟腈中的氮原子与PD-L1的Asn63形成了水介导的相互作用,这稳定了化合物与PD-L1的结合,为引入烟腈以增强抑制活性提供了重要且合理的解释。我们的研究为进一步设计有效的基于喹唑啉的小分子PD-L1抑制剂提供了有价值的指导,并确定了化合物7是一种有前途的先导化合物,值得进一步研究。

相似文献

1
Design, synthesis, evaluation and molecular modeling of quinazoline derivatives bearing amino acids as small-molecule PD-L1 inhibitors.作为小分子PD-L1抑制剂的含氨基酸喹唑啉衍生物的设计、合成、评估及分子模拟
J Comput Aided Mol Des. 2025 Jul 18;39(1):55. doi: 10.1007/s10822-025-00635-y.
2
Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.发现喹唑啉衍生物作为新型小分子抑制剂,靶向细胞程序性死亡-1/细胞程序性死亡配体 1(PD-1/PD-L1)相互作用。
Eur J Med Chem. 2022 Feb 5;229:113998. doi: 10.1016/j.ejmech.2021.113998. Epub 2021 Nov 18.
3
Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment.具有改善的类药性质和药代动力学特性用于癌症治疗的新型间苯二酚二苄基醚基PD-1/PD-L1抑制剂的发现与晶体学研究
J Med Chem. 2025 Jun 26;68(12):12593-12614. doi: 10.1021/acs.jmedchem.5c00344. Epub 2025 Jun 16.
4
Design, synthesis, and antitumor activity evaluation of 1,2,3-triazole derivatives as potent PD-1/PD-L1 inhibitors.1,2,3-三唑衍生物作为高效PD-1/PD-L1抑制剂的设计、合成及抗肿瘤活性评价
Bioorg Chem. 2024 Dec;153:107813. doi: 10.1016/j.bioorg.2024.107813. Epub 2024 Sep 7.
5
In silico identification of promising PD-L1 inhibitors from selected indian medicinal plants for treatment of triple negative breast cancer.通过计算机模拟从选定的印度药用植物中鉴定有前景的程序性死亡受体配体1(PD-L1)抑制剂用于治疗三阴性乳腺癌。
PLoS One. 2025 Jul 10;20(7):e0327475. doi: 10.1371/journal.pone.0327475. eCollection 2025.
6
Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs.磺酰基喹唑啉类似物作为有前景的肝癌药物的设计、合成、分子对接及评价
Bioorg Chem. 2024 Dec;153:107777. doi: 10.1016/j.bioorg.2024.107777. Epub 2024 Sep 1.
7
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.比较 PD-1/PD-L1 联合疗法在晚期 NSCLC 一线治疗中的疗效和安全性:一项更新的系统评价和网络荟萃分析。
Clin Transl Oncol. 2024 Oct;26(10):2488-2502. doi: 10.1007/s12094-024-03442-3. Epub 2024 Apr 16.
8
High-throughput screening identifies ibuprofen as an sEV PD-L1 inhibitor for synergistic cancer immunotherapy.高通量筛选鉴定布洛芬为一种外泌体 PD-L1 抑制剂,用于协同癌症免疫治疗。
Mol Ther. 2024 Oct 2;32(10):3580-3596. doi: 10.1016/j.ymthe.2024.08.027. Epub 2024 Aug 31.
9
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.晚期 NSCLC 中 PD-L1 的表达:系统文献回顾对风险分层和治疗选择的启示。
Lung Cancer. 2017 Oct;112:200-215. doi: 10.1016/j.lungcan.2017.08.005. Epub 2017 Aug 10.
10
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.在结直肠癌模型中,溶瘤呼肠孤病毒与PD1-PDL1抑制剂联合使用时可增强CEA免疫疗法的效果。
Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12.

本文引用的文献

1
Design, Synthesis, and Evaluation of 8-(-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists.8-(对甲苯基)喹唑啉衍生物作为小分子PD-1/PD-L1拮抗剂的设计、合成与评价
ACS Med Chem Lett. 2024 Mar 15;15(4):518-523. doi: 10.1021/acsmedchemlett.4c00014. eCollection 2024 Apr 11.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
发现具有新型骨架的高效小分子 PD-1/PD-L1 抑制剂用于癌症免疫治疗。
J Med Chem. 2024 Mar 14;67(5):4083-4099. doi: 10.1021/acs.jmedchem.3c02362. Epub 2024 Feb 13.
4
Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.基于片段偶联策略发现诱导 PD-L1 二聚化、内化和降解的新型 PD-L1 抑制剂。
J Med Chem. 2023 Dec 28;66(24):16807-16827. doi: 10.1021/acs.jmedchem.3c01534. Epub 2023 Dec 18.
5
Cancer immunotherapies: advances and bottlenecks.癌症免疫疗法:进展与瓶颈。
Front Immunol. 2023 Aug 24;14:1212476. doi: 10.3389/fimmu.2023.1212476. eCollection 2023.
6
Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2'-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors.设计、合成及 2-芳甲氧基-4-(2,2'-二卤代联苯-3-基甲氧基)苄基胺衍生物作为有效 PD-1/PD-L1 抑制剂的抗肿瘤活性评价。
J Med Chem. 2023 Aug 10;66(15):10579-10603. doi: 10.1021/acs.jmedchem.3c00731. Epub 2023 Jul 26.
7
Inside PD-1/PD-L1,2 with their inhibitors.在 PD-1/PD-L1 内及其抑制剂。
Eur J Med Chem. 2023 Aug 5;256:115465. doi: 10.1016/j.ejmech.2023.115465. Epub 2023 May 6.
8
RCSB Protein Data Bank: Efficient Searching and Simultaneous Access to One Million Computed Structure Models Alongside the PDB Structures Enabled by Architectural Advances.RCSB 蛋白质数据库:通过架构上的改进,实现了对 PDB 结构的高效搜索和同时访问一百万计算结构模型的功能。
J Mol Biol. 2023 Jul 15;435(14):167994. doi: 10.1016/j.jmb.2023.167994. Epub 2023 Feb 2.
9
Harnessing the cyclization strategy for new drug discovery.利用环化策略进行新药研发。
Acta Pharm Sin B. 2022 Dec;12(12):4309-4326. doi: 10.1016/j.apsb.2022.09.022. Epub 2022 Oct 7.
10
Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand.核因子-κB 配体受体激活剂的口服小分子抑制剂的开发。
J Med Chem. 2022 Aug 25;65(16):10992-11009. doi: 10.1021/acs.jmedchem.2c00081. Epub 2022 Aug 12.